CELL GENESYS INC|4Oct 15, 3:06 PM ET

CELL GENESYS INC 4

4 · CELL GENESYS INC · Filed Oct 15, 2009

Form 4

Period: 2009-10-14

Director

Transactions

Disposition to Issuer
Common Stock
2009-10-14−8,000→ 0 total
Disposition to Issuer
Stock Option (right to buy)
2009-10-14−7,500→ 0 total
Exercise: $5.02Exp: 2016-06-30→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2009-10-14−7,500→ 0 total
Exercise: $20.50Exp: 2011-06-29→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2009-10-14−7,500→ 0 total
Exercise: $10.39Exp: 2014-06-30→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2009-10-14−7,500→ 0 total
Exercise: $2.60Exp: 2018-06-30→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2009-10-14−7,500→ 0 total
Exercise: $3.47Exp: 2017-06-30→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Option (right to buy0
2009-10-14−7,500→ 0 total
Exercise: $5.35Exp: 2015-06-30→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Option (right to buy0
2009-10-14−7,500→ 0 total
Exercise: $8.81Exp: 2013-06-30→ Common Stock (7,500 underlying)
Disposition to Issuer
Stock Option (right to buy)
2009-10-14−7,500→ 0 total
Exercise: $13.48Exp: 2012-06-28→ Common Stock (7,500 underlying)

Footnotes (3)

[F1]Pursuant to the merger of Cell Genesys, Inc. with and into BioSante Pharmaceuticals, Inc. (the "Merger"), such shares were disposed of in exchange for 1,462 shares of BioSante common stock having a market value of $1.82 per share on the effective date of the Merger.
[F2]This option vested immediately on the day of grant.
[F3]This option was terminated for no consideration upon the effective time of the Merger.

Documents

1 file